Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oncolysin CD6

Drug Profile

Oncolysin CD6

Alternative Names: Anti-CD6-blocked ricin; Anti-T12-blocked ricin

Latest Information Update: 25 Nov 1998

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute; ImmunoGen; Nonindustrial source
  • Developer ImmunoGen; Nonindustrial source
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Leukaemia; Lymphoma; Renal transplant rejection; Systemic lupus erythematosus

Most Recent Events

  • 25 Nov 1998 Discontinued-I for Leukaemia in USA (IV-infusion)
  • 25 Nov 1998 Discontinued-I for Lymphoma in USA (IV-infusion)
  • 25 Nov 1998 Discontinued-Unspecified phase in Autoimmune disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top